Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
Daughter's warning after fitness coach dad died from lung disease at 69
Denham Thomas, from Hartlepool, saw his life drastically altered by Chronic Obstructive Pulmonary Disease, becoming dependent ...
Yicai Global6h
AstraZeneca Doubles Down on Chronic, Rare Disease Innovation in China
(Yicai) Sept. 30 -- AstraZeneca will strengthen its commitment to researching chronic and rare diseases in China, driving ...
Hosted on MSN9mon
Clearing Up Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease, or COPD, is an umbrella term for lungs with persistent diminished capacity and function caused by other lung-compromising conditions such as emphysema or ...
Rising Kashmir10d
Understanding COPD: A Chronic Lung Disease
Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...
Exclusive: Understanding Chronic Lung Diseases And Co-Morbidities
MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...
Too Old to Operate14d
Enhancing Pulmonary Rehabilitation in COPD with Virtual Reality
The following is a summary of “Virtual reality for COPD exacerbation: A randomized controlled trial,” published in the August ...
News Medical12h
Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery
Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and ...
World Lung Day: Vaccination Can Prevent Severe Pulmonary Diseases In India, Say Doctors; Know How They Work
Voluntary vaccination among adults can highly reduce the incidence of lung infections, say doctors on the occasion of World ...
Commit To Care: The Power of Adherence In Chronic Respiratory Disease Treatment
With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...
News Medical on MSN13d
Loneliness may not be a direct cause of disease
A study reveals loneliness correlates with 13 illness categories, highlighting its role as a potential proxy marker rather ...